Cordis purchases Flexible Stenting Solutions

12 March 2013 (Last Updated March 12th, 2013 18:30)

Cordis, an interventional vascular technology developer and part of the Johnson & Johnson family of companies, has purchased US-based Flexible Stenting Solutions for an undisclosed sum.

Cordis, an interventional vascular technology developer and part of the Johnson & Johnson family of companies, has purchased US-based Flexible Stenting Solutions for an undisclosed sum.

The acquisition will allow Cordis to develop its SMART vascular stent platform for the treatment of peripheral artery disease (PAD) with the addition of Flexible Stenting Solutions' FlexStent self-expanding stent system.

Designed to optimise flexibility, fracture resistance and radial strength with predictable placement, the FlexStent stent has received European CE Mark approval for the treatment of vascular disease and FDA 510(k) approval for the palliative treatment of biliary strictures associated with malignant tumors.

"The acquisition will allow Cordis to develop its SMART vascular stent platform for the treatment of peripheral artery disease with the addition of Flexible Stenting Solutions' FlexStent self-expanding stent system."

The FlexStent system is also being evaluated in an investigational device exemption open study to demonstrate the safety and efficacy of the device in the treatment of patients with atherosclerosis in the superficial femoral artery.

The addition of the FlexStent system also allows Cordis to expand therapeutic applications to below-the-knee and venous interventions.

Currently, SMART stent is approved for iliac, superficial femoral artery and proximal popliteal artery vascular indications in the US.

Cordis group chairman Shlomi Nachman said; "This acquisition will enable Cordis to provide clinicians more options to meet their evolving therapeutic needs and to strengthen our leadership position in the treatment of vascular disease."

Cardiovascular Research Foundation endovascular services director Dr William Gray said; "We are pleased to have the opportunity to learn more about the FlexStent system technology and its potential therapeutic applications for patients in the US beyond currently approved indications."